Related News
-
Clinuvel Reports Strong Phase…
Friday, July 16, 2010
Melbourne biotech Clinuvel has reported positive results from a Phase III trial of its UV protection drug Scenesse in… more...
-
Clinuvel Chooses US…
Thursday, July 8, 2010
Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced it had entered a long term… more...
-
Clinuvel Unveils SCENESSE(R)…
Thursday, May 20, 2010
Zurich -- Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that the European… more...
-
Italian Patients Request UV-…
Tuesday, May 18, 2010
Italian National Health System to reimburse afamelanotide for patients with porphyria (EPPItalian drug regulators have… more...
-
FDA Allows IND Status for…
Friday, January 30, 2009
Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announces that the US Food and Drug… more...
News
-
CheckOrphan NewsFlash April 30,…
4/30/2010
CheckOrphan NewsFlash for Tuesday, March 30, 2010: breaking news about rare diseases, orphan diseases, orphan drugs,…
-
CheckOrphan NewsFlash April 9,…
4/09/2010
CheckOrphan NewsFlash for Friday, April 9, 2010: breaking news about rare diseases, orphan diseases, orphan drugs, and…
-
CheckOrphan NewsFlash April 1,…
4/01/2010
CheckOrphan NewsFlash for Thursday, April 1, 2010: breaking news about rare diseases, orphan diseases, orphan drugs,…
NewsFlash
More News
-
Tot With Disorder Is 'the Happiest Kid'
When most people get a cold, they cough and sneeze and sniffle until it goes awayCharlie-… more...
-
Norfolk Baby's Life Hangs by a Thread
A community is rallying to fund comforts and pleasures for a seriously-ill north Norfolk… more...
-
Goddess Hair Extensions Founder…
SUNNYVALE, Calif. -- Sheila Matechuk, Developer of Goddess Hair Extensions &… more...
-
St. Jude, Chili's Expand Online Giving…
MEMPHIS, Tenn. - St. Jude Children's Research Hospital® and Chili's® Grill &… more...
-
Inaugural Fundraiser to Be Held to Stop…
The luminous glow of a firefly in the dark sky can be seen as a symbol of hope that… more...
People News
UAB's Joseph Bloomer Given AASLD 2009 Distinguished Service Award
| More
Thursday, October 29, 2009
BIRMINGHAM, Ala. -- Joseph Bloomer, M.D., professor of medicine in the Division of Gastroenterology and Hepatology and director of the Liver Center at University of Alabama at Birmingham (UAB), has received the 2009 Distinguished Service Award from the American Association for the Study of Liver Diseases (AASLD).
The AASLD Distinguished Service Award is given to an individual in honor of his or her sustained service to AASLD and/or the liver disease community in general.
Bloomer has served on seven committees of AASLD, even chairing the first research committee and chairing the task force for certificate of added qualification in transplant hepatology from 1997 to 2001. He was AASLD president from 1998 to 1999.
Bloomer also is a nationally recognized expert in liver diseases. He has worked on several national clinical trials in a variety of liver disorders and has received National Institutes of Health (NIH) research support since 1976, including a MERIT Award from 1994-2002 to investigate the pathogenesis of clinical and biochemical features in the group of genetic disorders called porphyrias. His laboratory was the first to define the enzyme defects in two of these eight disorders, erythropoietic protoporphyria (EPP) and variegate porphyria, and the first to show that liver disease in EPP is caused by the toxic effect of the molecule protoporphyrin on liver structure and function.
Most recently, Bloomer's laboratory has demonstrated that symptomatic disease in EPP is associated with a mutation in one allele of a gene that causes a harmful change in its enzyme structure, together with a polymorphism in the other allele of the gene that causes low gene expression. Bloomer also has clinical trials under way in the study of efficacy of therapy for hepatitis B and C.
Bloomer earned his bachelor's degree from the Massachusetts Institute of Technology and his medical degree from Case Western Reserve University, with research training in the NIH Metabolism Branch and a hepatology fellowship and faculty appointment at Yale University. Prior to joining the UAB faculty, he directed the University of Minnesota Division of Gastroenterology/Hepatology.
About UAB
The UAB Liver Center pioneers new treatments for liver and biliary tract disease. It offers specialized care through outpatient clinics and its inpatient hepatology service at UAB Hospital. The center also actively conducts clinical research activities. The UAB Liver Transplant Program has been ranked in the top 10 for patient-survival rates and has performed more than 1,200 transplants. The one-year survival rate is greater than 92 percent.
Media Contact:
Jennifer Lollar
(205) 934-3888
jpark@uab.edu
Source: University of Alabama at Birmingham (UAB)
Log in to comment.